Results 11 to 20 of about 38,538 (308)

Bispecific antibodies for viral immunotherapy [PDF]

Human Vaccines & Immunotherapeutics, 2017
Bispecific antibody engineering, in which binding specificities toward 2 distinct epitopes are combined into a single molecule, can greatly enhance immunotherapeutic properties of monoclonal antibodies.
Elisabeth K. Nyakatura, Alexandra Y. Soare, Jonathan R. Lai   +2 more
doaj   +3 more sources

Bispecific antibodies in follicular lymphoma

Haematologica
Bispecific antibodies, specifically anti-CD20 T-cell engaging constructs, are poised to alter the treatment paradigm of multiple B-cell malignancies, including follicular lymphoma.
Imran A. Nizamuddin, Nancy L. Bartlett
doaj   +3 more sources

Bispecific antibody therapies

Hematology, 2023
Abstract Management of hematological malignancies is rapidly evolving from chemotherapy-based regimens toward targeted agents and immunotherapies, including bispecific antibodies (BsAbs). These novel and highly active treatments come with new side effect profiles.
de Assis, Luiz Henrique, Fassi, Daniel El, Hutchings, Martin   +2 more
openaire   +3 more sources

Design and characterization of mouse IgG1 and IgG2a bispecific antibodies for use in syngeneic models

mAbs, 2020
The development of antibody therapeutics relies on animal models that accurately recapitulate disease biology. Syngeneic mouse models are increasingly used with new molecules to capture the biology of complex cancers and disease states, and to provide ...
Feng Wang, Jordan C. Tsai, Jonathan H. Davis, Bryant Chau, Jia Dong, Sean M. West, Jason M. Hogan, Matthew L. Wheeler, Christine Bee, Winse Morishige, Thomas Cayton, Donata David-brown, Chengyue Zhang, Alexander Kozhich, Tim Sproul, Gavin Dollinger, Arvind Rajpal, Pavel Strop   +17 more
doaj   +1 more source

A Bispecific Antibody That Simultaneously Recognizes the V2- and V3-Glycan Epitopes of the HIV-1 Envelope Glycoprotein Is Broader and More Potent than Its Parental Antibodies

mBio, 2020
Broadly neutralizing antibodies (bNAbs) can prevent and control an HIV-1 infection, but their breadth is invariably too limited for use as monotherapy. To address this problem, bi- and trispecific antibody-like constructs have been developed.
Meredith E. Davis-Gardner, Barnett Alfant, Jesse A. Weber, Matthew R. Gardner, Michael Farzan   +4 more
doaj   +1 more source

Selective engagement of FcγRIV by a M2e-specific single domain antibody construct protects against influenza A virus infection [PDF]

, 2019
Lower respiratory tract infections, such as infections caused by influenza A viruses, are a constant threat for public health. Antivirals are indispensable to control disease caused by epidemic as well as pandemic influenza A.
Ballegeer, Marlies, Creytens, Sarah, De Vlieger, Dorien, Hengel, Hartmut, Hoffmann, Katja, Nerinckx, Wim, Remaut, Han, Saelens, Xavier, Schepens, Bert, Van Hoecke, Lien, Van Molle, Inge   +10 more
core   +2 more sources

Nanobody based dual specific CARs [PDF]

, 2018
Recent clinical trials have shown that adoptive chimeric antigen receptor (CAR) T cell therapy is a very potent and possibly curative option in the treatment of B cell leukemias and lymphomas.
Abken, Hinrich, Bonte, Sarah, De Munter, Stijn, Goetgeluk, Glenn, Ingels, Joline, Kerre, Tessa, Pille, Melissa, Vandekerckhove, Bart, Weening, Karin   +8 more
core   +2 more sources

Bispecific antibodies

Drug Discovery Today, 2015
Bispecific antibodies have emerged as molecules with a multitude of ...
Kontermann, Roland E., Brinkmann, Ulrich
openaire   +3 more sources

Use of single-chain antibody derivatives for targeted drug delivery [PDF]

, 2016
Single-chain antibodies (scFvs), which contain only the variable domains of full-length antibodies, are relatively small molecules that can be used for selective drug delivery.
Ahmadzadeh, V., Erfani-Moghadam, V., Jaliani, H.Z., Khalili, M., Safdari, Y., Zarei, V.   +5 more
core   +1 more source

In Vivo Secretion of Bispecific Antibodies Recruiting Lymphocytic Effector Cells

Antibodies, 2013
Engineered Fc-lacking bispecific antibodies have shown an exceptionally high potency for recruiting lymphocyte effector cells and enhancing antitumor activity, which is under evaluation in several clinical trials.
Luis Alvarez-Vallina, Laura Sanz, Natalia Nuñez-Prado, Marta Compte   +3 more
doaj   +1 more source